Gilead's Kite ties itself to Refuge's gene expression platform in blood cancer CAR-T deal

Preview

来源: FierceBiotech

Kite Pharma hopes Refuge's gene expression science can help set sail to new CAR-Ts.

Gilead’s Kite Pharma has tied down a licensing deal for Refuge Biotechnologies’ gene expression platform in hopes of developing new blood cancer treatments and plans to take flight with a new generation of CAR-Ts.

Through the exclusive global licensing agreement, the California biotechs aim to create new CAR-T products to induce long-term remissions for more patients, Kite’s head of cell therapy research Francesco Marincola, M.D., said in an Oct. 20 release.

Kite, a biotech Gilead acquired for $11.9 billion in 2017, holds FDA approvals for two CAR-T products—nearly half of the five currently greenlighted therapies. All of the agency's nods have been for blood cancers, and getting a cell therapy to market for solid tumors has so far remained out of reach.

Under the terms of the new deal, Kite will cover all costs and activities related to R&D, manufacturing and commercialization. Kite will also pay out an undisclosed cash fee to Refuge and give the biotech the chance to obtain performance-based milestone payments.

In return, Kite will hold an exclusive license to Refuge’s library of synthetic gene expression programs for blood cancer indications. Refuge, an early-stage biotech developing “intelligent cell therapeutics” for cancer immunotherapy, uses an expression modulation strategy to switch specific genes on and off and control a gene’s cell expression. In 2018, the company closed its most recent funding round, a $25 million series B.

Meanwhile, Refuge will retain the rights to any potential solid tumor therapy programs.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。